New insider Jain Rachit claimed ownership of 27,722 shares (SEC Form 3)
$SDGR
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 05/16/2025 |
3. Issuer Name and Ticker or Trading Symbol
Schrodinger, Inc. [ SDGR ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock | 27,722(1) | D | |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Stock Option (right to buy) | (2) | 03/15/2034 | Common Stock | 35,000 | $26.04 | D | |
| Stock Option (right to buy) | (3) | 03/03/2035 | Common Stock | 15,990 | $21.24 | D | |
| Explanation of Responses: |
| 1. Includes 26,155 unvested restricted stock units ("RSUs"), comprised of 7,500 unvested RSUs that will vest in equal installments on each of April 15, 2026, 2027 and 2028, and (ii) 18,655 unvested RSUs that will vest in equal installments on each of March 4, 2026, 2027, 2028 and 2029, in each case, subject to the Reporting Person's continued service with the company. Each RSU represents a contingent right to receive one share of common stock of the Issuer. |
| 2. The option was granted on March 15, 2024. The shares underlying the option are scheduled to vest with respect to 25% of the shares on February 27, 2025 and the remainder are scheduled to vest in equal monthly installments through February 27, 2028, subject to the Reporting Person's continued service with the company. |
| 3. The option was granted on March 3, 2025. The shares underlying the option are scheduled to vest with respect to 25% of the shares on March 3, 2026 and the remainder are scheduled to vest in equal monthly installments through March 3, 2029, subject to the Reporting Person's continued service with the company. |
| Remarks: |
| Exhibit 24.1 Power of Attorney |
| /s/ Donald Shum, as attorney-in-fact for Rachit Jain | 05/22/2025 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||